Silence Therapeutics (NASDAQ:SLN) Earns Outperform Rating from William Blair

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “outperform” rating reiterated by analysts at William Blair in a report issued on Tuesday,RTT News reports.

Other equities analysts have also recently issued reports about the stock. Chardan Capital reissued a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Friday, November 15th. Morgan Stanley reaffirmed an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a report on Tuesday, October 8th. Finally, Jefferies Financial Group initiated coverage on Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Silence Therapeutics currently has a consensus rating of “Buy” and an average target price of $57.20.

Silence Therapeutics Trading Down 0.6 %

NASDAQ SLN opened at $6.93 on Tuesday. The company has a market cap of $207.40 million, a P/E ratio of -4.41 and a beta of 1.30. Silence Therapeutics has a 1 year low of $5.81 and a 1 year high of $27.72. The company has a fifty day simple moving average of $17.35 and a 200 day simple moving average of $18.86.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds have recently added to or reduced their stakes in SLN. SG Americas Securities LLC grew its position in shares of Silence Therapeutics by 10.5% during the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock valued at $151,000 after buying an additional 667 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Silence Therapeutics during the 3rd quarter valued at about $56,000. Y Intercept Hong Kong Ltd raised its stake in shares of Silence Therapeutics by 22.9% in the third quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company’s stock worth $383,000 after acquiring an additional 3,923 shares during the last quarter. Quarry LP bought a new stake in shares of Silence Therapeutics during the second quarter worth approximately $114,000. Finally, Marshall Wace LLP boosted its holdings in shares of Silence Therapeutics by 7.3% in the second quarter. Marshall Wace LLP now owns 149,397 shares of the company’s stock valued at $2,839,000 after buying an additional 10,206 shares during the period. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.